Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a hectic schedule this week filled with meetings and a speaking engagement. This explains the sporadic posting, other than the usual morning missives. Nonetheless, we are motoring along, thanks to a few cups of stimulation. So time to get on with it. Here are a few items of interest to help you cope with your own busy schedule. Hope you conquer the world today and do keep us in mind when something interesting pops. …

Merck (MRK) has begun to prepare for the departure of chief executive officer Ken Frazier and is focusing its search for an eventual successor on a pool of internal candidates, Bloomberg News writes. Last September, Merck disclosed that Frazier would remain beyond 2019, rolling back a policy that would have required him to retire when he turns 65 in December. But now, Merck is laying the groundwork for his exit, as well as that of its seasoned research and development leader Roger Perlmutter, who is 66.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.